Upcoming events – binary outcomes for Inflarx and Achieve
Inflarx looks to its lead asset in a rare skin disease, while smoking cessation success could trigger partnering talks for Achieve Life Sciences.
Upcoming events – Achillion fishes for complements as Aquestive tackles ALS
December will be a big month for Achillion's complement inhibitor and Aquestive's ALS hopes.
Hope on the horizon for rare kidney disease
Loosening of clinical requirements has encouraged more projects into the IgA nephropathy pipeline, with a steroid–based approach from Sweden’s Calliditas looking…
Small and mid-cap share price gains make up for majors
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.
The big launches of 2014 – where are they now?
The drugs of 2014 that went supernova and those that failed to make orbit.
